M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts
并购不再是大型制药企业的专利，中型药企纷纷加快“扫货”步伐

In what is shaping up to be one of the most active years for biopharma M&A on record, a different-looking set of buyers is going shopping.
在这个正逐渐成为史上最活跃的生物医药并购年份之一的市场中，一批面貌迥异的新买家开始出手。